NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announced it has enrolled the first patient in its Phase IIb PARADIGM trial for its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS).
PARADIGM will enroll 69 people living with ALS in Israel, Italy, and the U.S.
